Ozempic (semaglutide 1.0–2.0 mg) produces approximately 5–10% body weight loss as a secondary endpoint in diabetes trials (SUSTAIN program). Wegovy (semaglutide 2.4 mg), the FDA-approved weight loss version, showed 14.9% in the STEP 1 trial over 68 weeks. Individual results vary based on dose, duration, diet, and program adherence.
Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. For weight management, the same molecule is available as Wegovy, which is FDA-approved for chronic weight management. At PEAK, we prescribe Wegovy for weight-loss patients.
Clinical trial data
Ozempic’s weight loss data comes primarily from the SUSTAIN clinical trial program, which studied semaglutide for type 2 diabetes. Weight loss was a secondary endpoint:
- SUSTAIN-1: Semaglutide 0.5 mg produced ~3.7 kg weight loss; 1.0 mg produced ~4.5 kg over 30 weeks vs. placebo.
- SUSTAIN-6 (cardiovascular outcomes): Semaglutide groups lost 2.9–4.3 kg more than placebo over 2 years.
- Real-world data: Observational studies suggest 5–10% body weight loss over 6–12 months at Ozempic doses, though results vary and these patients were on various diabetes regimens.
For comparison, the STEP 1 trial (which studied semaglutide specifically for weight loss at the higher 2.4 mg Wegovy dose) showed an average of 14.9% body weight loss over 68 weeks. This is the gold-standard weight loss data for semaglutide.
Weight loss timeline
Semaglutide weight loss follows a predictable pattern:
- Weeks 1–4: Titration begins at low dose. Minimal weight loss (1–3 lbs). Appetite suppression starts gradually.
- Months 1–3: As dose increases, appetite suppression becomes more noticeable. Many patients lose 3–5% of body weight.
- Months 3–6: At maintenance dose, weight loss accelerates. Many patients see 5–8% of body weight lost at Ozempic doses.
- Months 6–12: Weight loss continues but slows. Most reach their maximum effect around 12–15 months.
- Beyond 12 months: Weight generally stabilizes. Continued use maintains the loss; stopping typically leads to partial regain.
Trial averages include both strong and weak responders. About one-third of patients in STEP 1 lost 20% or more of their body weight, while some lost less than 5%. Response varies by individual biology, adherence, and full program engagement.
Ozempic vs. Wegovy results
Ozempic and Wegovy contain the same semaglutide molecule, but differ in two important ways that affect weight loss results:
- Maximum dose. Ozempic caps at 2.0 mg; Wegovy goes to 2.4 mg. This extra dose matters — the STEP trial program studied the 2.4 mg dose specifically for weight loss.
- Study design. SUSTAIN (Ozempic) measured weight as a secondary diabetes endpoint. STEP (Wegovy) studied weight loss as the primary endpoint with weight-management-focused protocols.
For patients whose goal is maximum weight loss, Wegovy at 2.4 mg is the better semaglutide option.
What affects your results
- Dose achieved. Higher doses produce more weight loss. Reaching and maintaining the maximum tolerated dose matters.
- Nutrition. Patients who work with a dietitian and adjust their diet typically see better results than medication alone.
- Physical activity. Regular exercise, especially resistance training, preserves muscle mass and improves body composition.
- Program adherence. Consistent use, regular follow-ups, and engagement with the full treatment program produce the best outcomes.
- Starting weight. Patients with higher starting BMIs often lose more absolute weight.
PEAK’s approach
At PEAK, we don’t prescribe Ozempic for weight loss — we prescribe Wegovy at the higher weight-loss dose. But regardless of which semaglutide product you’ve been on, the principles for maximizing results are the same: proper titration, nutrition support, clinical monitoring, and patience.
Schedule a consultation to discuss realistic weight loss expectations and build a plan.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
